Regulatory Networks: Reality check for transposon enhancers

Hundreds of retrovirus-like sequences have features that suggest they might be gene enhancers, but only a small fraction displays gene-regulating activity in experiments on mouse stem cells.
  1. Julie Brind'Amour
  2. Dixie L Mager  Is a corresponding author
  1. University of British Columbia, Canada
  2. BC Cancer, Canada

First described over forty years ago, an enhancer is a genetic sequence that can 'switch on' a far away gene in certain tissues or at key points during development by interacting with the promoter for that gene. While promoters are generally conserved between organisms, enhancers are often unique to a given species, suggesting that they have evolved more recently (reviewed in Long et al., 2016).

One source of species-specific enhancers might be transposable elements, DNA sequences that can copy themselves and jump to another location in the genome (or simply move to another place). Many of these elements are derived from retroviruses whose genetic code has permanently colonized the genome of their hosts (also known as endogenous retrovirus-like elements, or ERVs). In humans and mice, over 40% of chromosomal DNA is made of transposable elements. Although the vast majority are no longer capable of jumping, they are responsible for much of the genomic diversity across species.

To successfully spread through the genome, these sequences contain their own regulatory components, including enhancers and promoters. Whether cells have then ‘domesticated’ transposable elements for their own advantage – and in particular, whether certain sequences can act as dispersed ‘controlling elements’ in regulatory gene networks – has been a topic of interest for half a century (Britten and Davidson, 1969; Chuong et al., 2017), with this concept gaining momentum in the last decade.

Indeed, genome-wide studies have revealed that transposable elements can show traits associated with enhancers, such as being able to bind to transcription factors or displaying characteristic epigenetic and chromatin features (Kunarso et al., 2010; Chuong et al., 2013). These discoveries have fuelled models in which transposable elements are being co-opted to act as enhancers.

Enhancer-like epigenetic features and binding sites for transcription factors are particularly common in regions of ERVs called long terminal repeats. Still, the evidence which shows that these elements have enhancer activity remains provocative. As with any putative enhancer, the challenge is now to go beyond analyses which demonstrate correlations and towards studies that rigorously validate that transposable elements can work as enhancers (as discussed in Chuong et al., 2017). Now, in eLife, Miguel Branco and colleagues at Queen Mary University of London – including Christopher Todd as first author – report that such assessment is, indeed, critically needed (Todd et al., 2019).

The team examined families of ERVs whose long terminal repeats can bind to transcription factors and which show the classic epigenetic features associated with enhancers, such as open chromatin and certain histone modifications (Figure 1A). In particular, they focused on elements that had been reported to contain binding sites for key transcription factors which are specific to mouse embryonic or trophoblast stem cells (Kunarso et al., 2010; Chuong et al., 2013; Sundaram et al., 2017). This allowed Todd et al. to identify putative enhancers overlapping with long terminal repeats (roughly 630 elements in embryonic stem cells and 360 in trophoblast stem cells). These elements are called ‘TE+ enhancers’ to distinguish them from traditional ‘TE- enhancers’, which do not share sequences with transposable elements. Most putative TE+ enhancers in embryonic stem cells have already been described, but Todd et al. highlight that these are more specific to certain types of cells than TE- enhancers.

Functional validation of putative TE+ enhancers.

Here, the long terminal repeats belonging to the RLTR13D6 family are used to demonstrate how putative enhancers can be validated. (A) Of the 805 copies of RLTR13D6 sequences (blue boxes) in the mouse genome, 76 have an ‘enhancer-like’ chromatin state in embryonic stem cells and bind at least one key transcription factor in this cell type (green stars). (B) High-throughput plasmid-based reporter assays work by inserting a potential enhancer sequence into a plasmid (black circle), and examining its impact on the expression of a reporter gene (dark purple box). Only a third of the long terminal repeats that show enhancer activity in these assays have an enhancer-like chromatin state in the genome (dark green fraction of the pie chart). (C) Promoter capture Hi-C experiments showed that about a third of the putative enhancers (dark green fraction of the pie chart) interacted with the promoter of at least one gene (purple boxes). (D) Disrupting RLTR13D6 long terminal repeats using CRISPR interference reduced the histone mark H3K27ac (a sign of enhancer function) by at least two fold for 34 of the 76 sequences (light green). Using RNA-seq after CRISPR interference showed that only three genes associated with an RLTR13D6 element were down-regulated by at least 1.5 fold. (E) In embryonic stem cells, CRISPR-Cas9 deletion (blue box disappearing) of four long terminal repeats with enhancer signatures reduced gene expression in only one case.

Plasmid-based reporter assays work by inserting a sequence of interest into a plasmid, and evaluating its impact on the expression of a reporter gene; these experiments have already demonstrated that, in vitro, transposable elements with certain transcription factor binding motifs could play the role of enhancers (Sundaram et al., 2017). Looking at long terminal repeats in which such assays had highlighted a potential enhancer activity, Todd et al. found that, in situ in the genome, only a third of them had chromatin features that were compatible with an enhancer role (Figure 1B). This means that specific sequence features are not enough to predict whether a transposable element works as an enhancer when in the genome: the broader chromatin context in which the element is embedded likely influences whether enhancer-like features can appear.

Since enhancers can act over large distances, Todd et al. took advantage of their previously published promoter chromatin-capture data to identify which genes the putative TE+ enhancers could target. Compared to TE- enhancers, only about 40% of TE+ enhancers were found to physically interact with at least one gene promoter (Figure 1C). These target genes were expressed almost exclusively in embryonic or trophoblast stem cells, which is consistent with the epigenetic profile of TE+ enhancers. In contrast, TE- enhancers tended to interact with genes expressed in a broader range of tissues; this highlights that transposable elements acquire their enhancer-like features in ways that are specific to a cell type.

Finally, Todd et al. harnessed a combination of specific CRISPR-Cas9 deletions and widespread CRISPR interference (Gilbert et al., 2013) to test how TE+ enhancers influenced the expression of the genes they target. The results showed that deleting putative enhancers did not always affect gene expression. In addition, when 76 putative enhancers belonging to the RLTR13D6 family were disrupted in embryonic stem cells, only three of their target genes showed significant reduction in transcription (Figure 1D,E). Chromatin features and exogenous plasmid-based assays can help to map new candidate enhancer regions, but the Branco’s group showcases that, alone, these assays are not enough to confirm enhancer function.

This low validation rate reflects several difficulties that emerge when assessing if sequences with tantalizing epigenomic characteristics are indeed enhancers (discussed in Halfon, 2019). Recent work in humans has demonstrated that primate-specific long terminal repeats are also used as enhancers in human embryonic stem cells (Fuentes et al., 2018; Pontis et al., 2019). Unlike the mouse experiments of Todd et al., the human studies yielded a much higher proportion of putative TE+ enhancers with an impact on gene transcription upon in situ targeting with CRISPR interference. It is not clear whether these differences are due to variations in techniques and significance thresholds, or because humans and mice recruit families of long terminal repeats with enhancer-like roles at a different pace. Nonetheless, this body of work strengthens the theory that transposable elements can act as enhancers, while also highlighting that careful, in situ evaluation is required before any candidate region is given a definite enhancer role.

References

Article and author information

Author details

  1. Julie Brind'Amour

    Julie Brind'Amour is in the Department of Medical Genetics, University of British Columbia, Vancouver, Canada

    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9522-8571
  2. Dixie L Mager

    Dixie L Mager is in the Department of Medical Genetics, University of British Columbia, Vancouver, Canada and the Terry Fox Laboratory, BC Cancer, Vancouver, Canada

    For correspondence
    dmager@bccrc.ca
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5955-2550

Publication history

  1. Version of Record published: May 31, 2019 (version 1)

Copyright

© 2019, Brind'Amour and Mager

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,815
    Page views
  • 214
    Downloads
  • 2
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Julie Brind'Amour
  2. Dixie L Mager
(2019)
Regulatory Networks: Reality check for transposon enhancers
eLife 8:e47900.
https://doi.org/10.7554/eLife.47900

Further reading

    1. Chromosomes and Gene Expression
    2. Developmental Biology
    Lewis Macdonald et al.
    Tools and Resources

    Auxin-inducible degrons are a chemical genetic tool for targeted protein degradation and are widely used to study protein function in cultured mammalian cells. Here we develop CRISPR-engineered mouse lines that enable rapid and highly specific degradation of tagged endogenous proteins in vivo. Most but not all cell types are competent for degradation. By combining ligand titrations with genetic crosses to generate animals with different allelic combinations, we show that degradation kinetics depend upon the dose of the tagged protein, ligand, and the E3 ligase substrate receptor TIR1. Rapid degradation of condensin I and condensin II - two essential regulators of mitotic chromosome structure - revealed that both complexes are individually required for cell division in precursor lymphocytes, but not in their differentiated peripheral lymphocyte derivatives. This generalisable approach provides unprecedented temporal control over the dose of endogenous proteins in mouse models, with implications for studying essential biological pathways and modelling drug activity in mammalian tissues.

    1. Cell Biology
    2. Chromosomes and Gene Expression
    Jakub Gemperle et al.
    Tools and Resources

    CRISPR technology has made generation of gene knock-outs widely achievable in cells. However, once inactivated, their re-activation remains difficult, especially in diploid cells. Here, we present DExCon (Doxycycline-mediated endogenous gene Expression Control), DExogron (DExCon combined with auxin-mediated targeted protein degradation), and LUXon (light responsive DExCon) approaches which combine one-step CRISPR-Cas9-mediated targeted knockin of fluorescent proteins with an advanced Tet-inducible TRE3GS promoter. These approaches combine blockade of active gene expression with the ability to re-activate expression on demand, including activation of silenced genes. Systematic control can be exerted using doxycycline or spatiotemporally by light, and we demonstrate functional knock-out/rescue in the closely related Rab11 family of vesicle trafficking regulators. Fluorescent protein knock-in results in bright signals compatible with low-light live microscopy from monoallelic modification, the potential to simultaneously image different alleles of the same gene, and bypasses the need to work with clones. Protein levels are easily tunable to correspond with endogenous expression through cell sorting (DExCon), timing of light illumination (LUXon), or by exposing cells to different levels of auxin (DExogron). Furthermore, our approach allowed us to quantify previously unforeseen differences in vesicle dynamics, transferrin receptor recycling, expression kinetics, and protein stability among highly similar endogenous Rab11 family members and their colocalization in triple knock-in ovarian cancer cell lines.